Resultado da Busca
14 de out. de 2020 · Widespread HPV vaccine use dramatically reduces the number of women who will develop cervical cancer, a large study has shown. In the study of nearly 1.7 million women, the vaccine was particularly effective for girls vaccinated before age 17, among whom there was a nearly 90% reduction in cervical cancer incidence.
Cervical cancer starts in the cells on the surface of the cervix. Most cancers in the cervix are caused by cell changes from the human papillomavirus (HPV). HPV is a very common virus that is passed on by sexual contact. There are many different types of HPV. Some types can cause cancer and are called high-risk types.
30 de set. de 2020 · Cervical cancer was diagnosed in 19 women who had received the quadrivalent HPV vaccine and in 538 women who had not received the vaccine. The cumulative incidence of cervical cancer was 47 cases ...
Women who have received HPV vaccine are recommended to undergo cervical screening through the National Cervical Screening Program according to the Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. 5 HPV types other than those included in the HPV vaccines can cause cervical cancer.
The American Cancer Society's Mission: HPV Cancer Free is a public health initiative to eliminate vaccine preventable HPV cancers as a public health problem, starting with cervical cancer. Our goal is to reach an annual vaccination rate of 80% of 13-year-olds in the United States by 2026.
16 de dez. de 2022 · All vaccines are highly efficacious in preventing infection with virus types 16 and 18, which are together responsible for approximately 70% of cervical cancer cases globally. The vaccines are also highly efficacious in preventing precancerous cervical lesions caused by these virus types.
6 de mar. de 2024 · A vaccine to prevent HPV infection with oncogenic-type viruses has the potential to reduce the incidence of cervical cancer. A vaccine against HPV-16 using empty-viral capsids called virus-like particles (VLP) was developed and tested for efficacy in preventing persistent infection with HPV-16.
